Aclaris Therapeutics posted modest quarterly revenue in Q2 2024, underscoring its status as a clinical-stage biotechnology company with a dual revenue model (Therapeutics pipeline development and Contract Research Organization (CRO) services). Revenue for the quarter was $2.766 million, up 15.3% QoQ and 48.0% YoY, while gross profit reached $0.857 million (gross margin ~31%), indicating improving product mix relative to earlier quarters. However, the company recorded a net loss of $10.986 million and an EBITDA of −$12.612 million, with operating expenses totaling $13.411 million, reflecting ongoing heavy investment in R&D and administrative activities typical of late-stage pre-commercial biotech programs.
Significant cash and investment holdings provided a robust liquidity buffer (cash and short-term investments of $111.093 million and cash at period end of $22.834 million), supporting the company’s long-run strategic pipeline and CRO capabilities. The balance sheet remains solid with total assets of $161.071 million and total stockholders’ equity of $133.822 million, while liabilities are modest ($27.249 million total). Net debt stands at approximately −$20.0 million, signaling a net cash position driven by sizable investments and favorable financing conditions.
The quarter’s results highlight a classic growth-and-investment phase: meaningful YoY and QoQ revenue growth, improving gross margins, and sustained cash runway, but with no near-term path to GAAP profitability given continued R&D intensity and pipeline development costs. Investors should monitor pipeline milestones (ATI1777, ATI2138, ATI2231), potential partnership or out-licensing opportunities, and any shifts in CRO revenue mix that could meaningfully alter cash burn and liquidity scenarios.